TY - JOUR
T1 - The rabbit papillomavirus model
T2 - A valuable tool to study viral-host interactions
AU - Cladel, Nancy M.
AU - Peng, Xuwen
AU - Christensen, Neil
AU - Hu, Jiafen
N1 - Funding Information:
Research reported in this publication was supported by the National Cancer Institute under award number R01 CA47622 (N.C.), NIH contract HHSN272201000020I (N.C.) and the Jake Gittlen Memorial Golf Tournament.
Publisher Copyright:
© 2019 The Author(s) Published by the Royal Society. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Cottontail rabbit papillomavirus (CRPV) was the first DNA virus shown to be tumorigenic. The virus has since been renamed and is officially known as Sylvilagus floridanus papillomavirus 1 (SfPV1). Since its inception as a surrogate preclinical model for high-risk human papillomavirus (HPV) infections, the SfPV1/rabbit model has been widely used to study viral - host interactions and has played a pivotal role in the successful development of three prophylactic virus-like particle vaccines. In this review, we will focus on the use of the model to gain a better understanding of viral pathogenesis, gene function and host immune responses to viral infections. We will discuss the application of the model in HPV-associated vaccine testing, in therapeutic vaccine development (using our novel HLA-A2.1 transgenic rabbits) and in the development and validation of novel anti-viral and anti-tumour compounds. Our goal is to demonstrate the role the SfPV1/ rabbit model has played, and continues to play, in helping to unravel the intricacies of papillomavirus infections and to develop tools to thwart the disease. This article is part of the theme issue 'Silent cancer agents: multi-disciplinary modelling of human DNA oncoviruses'.
AB - Cottontail rabbit papillomavirus (CRPV) was the first DNA virus shown to be tumorigenic. The virus has since been renamed and is officially known as Sylvilagus floridanus papillomavirus 1 (SfPV1). Since its inception as a surrogate preclinical model for high-risk human papillomavirus (HPV) infections, the SfPV1/rabbit model has been widely used to study viral - host interactions and has played a pivotal role in the successful development of three prophylactic virus-like particle vaccines. In this review, we will focus on the use of the model to gain a better understanding of viral pathogenesis, gene function and host immune responses to viral infections. We will discuss the application of the model in HPV-associated vaccine testing, in therapeutic vaccine development (using our novel HLA-A2.1 transgenic rabbits) and in the development and validation of novel anti-viral and anti-tumour compounds. Our goal is to demonstrate the role the SfPV1/ rabbit model has played, and continues to play, in helping to unravel the intricacies of papillomavirus infections and to develop tools to thwart the disease. This article is part of the theme issue 'Silent cancer agents: multi-disciplinary modelling of human DNA oncoviruses'.
UR - http://www.scopus.com/inward/record.url?scp=85064478626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064478626&partnerID=8YFLogxK
U2 - 10.1098/rstb.2018.0294
DO - 10.1098/rstb.2018.0294
M3 - Review article
C2 - 30955485
AN - SCOPUS:85064478626
SN - 0962-8436
VL - 374
JO - Philosophical Transactions of the Royal Society B: Biological Sciences
JF - Philosophical Transactions of the Royal Society B: Biological Sciences
IS - 1773
M1 - 20180294
ER -
